Key Insights

Highlights

Treatment Research

3 treatments under study, led by 225acacaky2519 Therapeutic

Related Conditions

Often studied with 15 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
Early Phase 1 (1)
Phase 1 (2)

Trial Status

Recruiting3

Clinical Trials (3)

Showing 3 of 3 trials
NCT07581184Phase 1Recruiting

A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT07887971Phase 1Recruiting

A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors

NCT06454955Early Phase 1RecruitingPrimary

Study on B7-H3 Targeted Affibody Radioligand Probes for PET Imaging of Solid Tumors

Showing all 3 trials

Research Network

Common Treatments

  • 225acacaky2519 Therapeutic2
  • 64cucuaky2519 Imaging2
  • 68ga B7h3 Affibodybch1

Active Sponsors

  • Aktis Oncology, Inc.2
  • Peking University Cancer Hospital & Institute1

Related Conditions

  • Prostate Cancer2
  • Mcrpc Metastatic Castrationresistant Prostate Cancer2
  • Hnscc1
  • Head Neck Cancer Squamous Cell Metastatic1
  • Mcrpc1

Activity Timeline